All In Biotech

NDA 017588 · Azurity

Gleostine

Lomustine · Oral · Alkylating Drug

Novel

Last checked: Nov 20, 2026Latest source record: Jun 4, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Aug 4, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

135

49 Phase 3, 15 recruiting

FAERS reports

2,597

1,796 serious, 587 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DELAYED MYELOSUPPRESSION and RISK OF OVERDOSAGE DELAYED MYELOSUPPRESSION Lomustine causes myelosuppression including fatal myelosuppression. Myelosuppression is delayed, dose-related, and cumulative; occurring 4 to 6 weeks after drug administration and persisting for 1 to 2 weeks. Thrombocytopenia is generally more severe than leukopenia. Cumulative myelosuppression from lomustine is manifested by greater severity and longer duration of cytopenias. Monitor blood counts for at least 6 weeks after each dose. Do not give lomustine more frequently than every 6 weeks [see Warnings and Precautions ( 5.1 ), Dosage and Administration ( 2.2 , 2.3 )] . RISK OF OVERDOSAGE PRESCRIBE, DISPENSE, AND ADMINISTER ONLY ENOUGH CAPSULES FOR ONE DOSE. Fatal toxicity occurs with overdosage of lomustine . Both physician and pharmacist should emphasize to the patient that only one dose of lomustine is...

What it is approved for

From the label in effect Feb 12, 2026.

Lomustine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. ( 1 ) 1.1 Brain Tumors Lomustine is indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical and/or radiotherapeutic procedures. 1.2 Hodgkin's Lymphoma Lomustine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma whose disease has progressed following initial chemotherapy.

Mechanism: Lomustine alkylates DNA and RNA. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 4, 1976 Original approval · Type 1 - New Molecular Entity
4 products under this application
  • GLEOSTINE · LOMUSTINE 40MG · CAPSULE, ORAL · Prescription · TE AB
  • GLEOSTINE · LOMUSTINE 100MG · CAPSULE, ORAL · Prescription · TE AB
  • GLEOSTINE · LOMUSTINE 10MG · CAPSULE, ORAL · Prescription · TE AB
  • GLEOSTINE · LOMUSTINE 5MG · CAPSULE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Lomustine" as an intervention, any sponsor and status, largest first.

All 135 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death273
  • off label use254
  • nausea232
  • fatigue219
  • thrombocytopenia187
  • disease progression144
  • neutropenia134
  • drug ineffective126
  • platelet count decreased114
  • vomiting110
  • seizure92
  • headache87

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20053
20067
200711
200811
200921
201026
201116
201254
201330
201454
201573
201694
2017247
2018298
2019291
2020232
2021238
2022222
2023219
2024156
2025152
2026134

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gleostine (Lomustine)

2024 spending

$3.5M

Beneficiaries

831

2,969 claims

Per beneficiary

$4,183

$692.68 per unit

View as table
YearSpending
2020$2,536,478
2021$24,112
2022$0
2023$2,702,189
2024$3,476,288

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 284 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.